Connecticut Top Court Confirms Defense Win in Pradaxa Litigation
Connecticut’s top court has confirmed a defense verdict delivered in the first case to go to trial out of thousands of lawsuits claiming Boehringer Ingelheim did not warn of the risks of severe bleeding linked with its blood thinner drug Pradaxa.
The Connecticut Supreme Court on Monday rejected arguments by Mary Boone’s daughter that a trial judge improperly concluded federal law. The court obtained some of her claims and stopped her from presenting evidence about records the company lost or destroyed.
In 2014 the German drug manufacturer Boehringer Ingelheim spent $650 million to settle nearly 4,000 Pradaxa lawsuits. The plaintiffs stated that in 2011 the anti-coagulant was the reason for 540 deaths and several other injuries because of uncontrolled bleeding that could not be stopped.
That was the leading cause of adverse event reports registered that year for tracked drugs. The hemorrhaging included rectal, esophageal, and brain bleeding. It took four years (in 2015) for the FDA to release the approved Praxbind as a fast-acting Pradaxa antidote. The FDA had approved Pradaxa as an alternative to the blood-thinning drug in 2010.
Pradaxa lawsuits stated that Boehringer Ingelheim did not notify and misled doctors and patients about the side effects of the drug. The plaintiffs alleged that Pradaxa’s labels have no warnings about potential gastrointestinal bleeding, especially in patients who suffered gastrointestinal problems, as well as about the risk of bleeding in elderly patients and other at-risk populations.
Pradaxa is used to lower the risk of stroke and blood clots in people who have atrial fibrillation issues. Besides that, the drug is also used to treat blood clots in the veins of the legs (deep vein thrombosis, or DVT), lungs and reduce the risk of them occurring again.
If you have issues using this drug, check our website at hurt.com.
Can a Damaged Road Lead to a Car Accident?
Nephrologists Are Reluctant to Accept Janssen’s INVOKANA